NASDAQ:TALS
Delisted

Talaris Therapeutics Stock Forecast

etoro logo Buy TALS
*Your capital is at risk
$2.72
+0 (+0%)
At Close: Dec 14, 2023

TALS Performance

TALS Dividend Payout History


# Declaration Date Ex-Date Pay Date Amount Yield
1 Oct 19, 2023 Oct 19, 2023 Oct 20, 2023 $1.51 55.58%

FAQ

What is the symbol for Talaris Therapeutics, Inc. Stock and on which exchange is it traded?
The symbol for Talaris Therapeutics, Inc. is TALS and it is traded on the NASDAQ (NASDAQ Stock Exchange).

Should I buy or sell Talaris Therapeutics, Inc. Stock?
Based on market data through Dec 14, 2023, StockInvest.us rates Talaris Therapeutics, Inc. (TALS) as Hold/Accumulate with a technical score of 0.00 on its -10 to +10 scale. The rating is unchanged from the previous daily evaluation. Since the Hold signal began on Oct 23, 2023, the price has remained flat. The current 3-month trend forecast projects a fall of 3.74%.

How to buy Talaris Therapeutics, Inc. Stock?
Talaris Therapeutics, Inc. Stock can be purchased through just about any brokerage firm, including online brokerage services.
Click here for our free guide on how to buy Talaris Therapeutics, Inc. Stock.

What's the current price of Talaris Therapeutics, Inc. Stock?
As of the end of day on the Dec 14, 2023, the price of an Talaris Therapeutics, Inc. (TALS) share was $2.72.

What is the 52-week high and low for Talaris Therapeutics, Inc. Stock?
The 52-week high for Talaris Therapeutics, Inc. Stock is $3.29 and the 52-week low is $0.89.

What is the market capitalization of Talaris Therapeutics, Inc. Stock?
As of the Dec 14, 2023, the market capitalization of Talaris Therapeutics, Inc. is 116.445M.
Click to get the best stock tips daily for free!
ABOUT TALARIS THERAPEUTICS, INC.
Talaris Therapeutics
Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in...
GOLDEN STAR
Ticker Change Signal Date
FCX
$62.63
7.46% Jul 31
MC
$67.08
2.40% Jul 31
ARW
$212.85
6.96% Jul 30
BIIB
$202.19
3.10% Jul 24
F
FERG
$230.67
10.77% Jul 24

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE